Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214734 · ClinicalTrials.gov registry record
ADVATE Post Authorization Safety Surveillance
A clinical trial of Hemophilia A, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 108
- Enrollment target
- 20
- Study locations
NCT00214734 is a study of Hemophilia A that has completed, run by Baxalta now part of Shire. The registered enrollment target is 108 participants, above the 89-participant average among 42 other Hemophilia A trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT00214734, a study of Hemophilia A, has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 108 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this post-authorization safety surveillance is to measure the incidence of adverse events that are at least possibly related to ADVATE use, in subjects receiving ADVATE in routine clinical practice.
Conditions Studied
Interventions
- DRUG rAHF-PFM
Study Locations (20)
Florida
- Children'S Hospital of S.W. Florida - Fort Myers
- BIODORON - Hollywood
- Nemours Children'S Clinic - Jacksonville
- NEMOURS CHILDREN'S CLINIC- Orlando - Orlando
- Tampa Children'S Hospital At St. Joes - Tampa
- University of Southern Florida - Tampa
California
- City of Hope National Medical Center - Duarte
- LONG BEACH MEMORIAL MED Center - Long Beach
- Children´s Hospital Los Angeles, Hemophilia Comprehensive Care Center, Division of Pediatric Hematology/Oncology - Los Angeles
- Valley Children'S Hospital - Madera
Illinois
- Rush Presbyterian - St. Lukes Medical Center - Chicago
- Children´s Memorial Hospital - Chicago
Michigan
- University of Michigan Med. Ctr Htc - Ann Arbor
- Henry Ford Hospital - Detroit
Arizona
- PHOENIX CHILDRENS Hospital - Phoenix
Arkansas
- Arkansas Childrens Hospital - Little Rock
Indiana
- Indiana Hemophilia & Thrombosis Center - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics, Iowa Regional Hemophilia Center, Department of Pediatrics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2004-10-14 |
| Est. Completion | 2007-03-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00214734
The ClinicalTrials.gov registry entry for NCT00214734 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 89-participant average among 42 other Hemophilia A trials with a reported enrollment target (21% higher). The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which rAHF-PFM is the first listed.
NCT00214734 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00214734 about?
NCT00214734 is a clinical study titled "ADVATE Post Authorization Safety Surveillance". The primary objective of this post-authorization safety surveillance is to measure the incidence of adverse events that are at least possibly related to ADVATE use, in subjects receiving ADVATE in routine clinical practice.
What is the current status of trial NCT00214734?
This trial is currently completed. The enrollment target is 108 participants. The study started on 2004-10-14. Estimated completion is 2007-03-02.
What conditions does trial NCT00214734 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT00214734?
The interventions under investigation include: rAHF-PFM (DRUG).
Who is sponsoring clinical trial NCT00214734?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00214734 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
Hemophilia A Research Program
RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.